Per new data it presented at the Obesity Week 2024 conference on Nov. 4, the investment thesis in favor of buying Viking is stronger than ever before, as there's more evidence supporting the idea that ...
The Motley Fool on MSN2d
Is Viking Therepautics a Buy Now?Wall Street's been pounding the table on Viking Therapeutics because VK2735 could become the next and best dual GLP-1/GIP ...
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback